Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling

Kentaro Suina, Kenji Tsuchihashi, Juntaro Yamasaki, Shohei Kamenori, Subaru Shintani, Yuki Hirata, Shogo Okazaki, Oltea Sampetrean, Eishi Baba, Koichi Akashi, Yoichiro Mitsuishi, Fumiyuki Takahashi, Kazuhisa Takahashi, Hideyuki Saya, Osamu Nagano

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas. System xc(–) consists of xCT and CD98hc subunits and functions as a plasma membrane antiporter for the uptake of extracellular cystine in exchange for intracellular glutamate. We previously showed that the EGF receptor (EGFR) interacts with xCT and thereby promotes the activity of system xc(–) in a kinase-independent manner, resulting in enhanced glutamate release in glioma cells. However, the molecular mechanism underlying EGFR-mediated glioma progression in a glutamate-rich microenvironment has remained unclear. Here we show that the GluN2B subunit of the N-methyl-d-aspartate–sensitive glutamate receptor (NMDAR) is a substrate of EGFR in glioma cells. In response to EGF stimulation, EGFR phosphorylated the COOH-terminal domain of GluN2B and thereby enhanced glutamate-NMDAR signaling and consequent cell migration in EGFR-overexpressing glioma cells. Treatment with the NMDAR inhibitor MK-801 or the system xc(–) inhibitor sulfasalazine suppressed EGF-elicited glioma cell migration. The administration of sulfasalazine and MK-801 also synergistically suppressed the growth of subcutaneous tumors formed by EGFR-overexpressing glioma cells. Furthermore, shRNA-mediated knockdown of xCT and GluN2B cooperatively prolonged the survival of mice injected intracerebrally with such glioma cells. Our findings thus establish a central role for EGFR in the signaling crosstalk between xCT and GluN2B-containing NMDAR in glioma cells.

元の言語英語
ページ(範囲)3874-3882
ページ数9
ジャーナルCancer Science
109
発行部数12
DOI
出版物ステータス出版済み - 12 1 2018

Fingerprint

Glutamate Receptors
Epidermal Growth Factor Receptor
Glioma
Glutamic Acid
Epidermal Growth Factor
Sulfasalazine
Dizocilpine Maleate
Cell Movement
Antiporters
Cystine
Brain Neoplasms
Small Interfering RNA
Phosphotransferases
Cell Membrane
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling. / Suina, Kentaro; Tsuchihashi, Kenji; Yamasaki, Juntaro; Kamenori, Shohei; Shintani, Subaru; Hirata, Yuki; Okazaki, Shogo; Sampetrean, Oltea; Baba, Eishi; Akashi, Koichi; Mitsuishi, Yoichiro; Takahashi, Fumiyuki; Takahashi, Kazuhisa; Saya, Hideyuki; Nagano, Osamu.

:: Cancer Science, 巻 109, 番号 12, 01.12.2018, p. 3874-3882.

研究成果: ジャーナルへの寄稿記事

Suina, K, Tsuchihashi, K, Yamasaki, J, Kamenori, S, Shintani, S, Hirata, Y, Okazaki, S, Sampetrean, O, Baba, E, Akashi, K, Mitsuishi, Y, Takahashi, F, Takahashi, K, Saya, H & Nagano, O 2018, 'Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling', Cancer Science, 巻. 109, 番号 12, pp. 3874-3882. https://doi.org/10.1111/cas.13826
Suina, Kentaro ; Tsuchihashi, Kenji ; Yamasaki, Juntaro ; Kamenori, Shohei ; Shintani, Subaru ; Hirata, Yuki ; Okazaki, Shogo ; Sampetrean, Oltea ; Baba, Eishi ; Akashi, Koichi ; Mitsuishi, Yoichiro ; Takahashi, Fumiyuki ; Takahashi, Kazuhisa ; Saya, Hideyuki ; Nagano, Osamu. / Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling. :: Cancer Science. 2018 ; 巻 109, 番号 12. pp. 3874-3882.
@article{e3aa1a51135b4b3cadb2333338c600c4,
title = "Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling",
abstract = "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas. System xc(–) consists of xCT and CD98hc subunits and functions as a plasma membrane antiporter for the uptake of extracellular cystine in exchange for intracellular glutamate. We previously showed that the EGF receptor (EGFR) interacts with xCT and thereby promotes the activity of system xc(–) in a kinase-independent manner, resulting in enhanced glutamate release in glioma cells. However, the molecular mechanism underlying EGFR-mediated glioma progression in a glutamate-rich microenvironment has remained unclear. Here we show that the GluN2B subunit of the N-methyl-d-aspartate–sensitive glutamate receptor (NMDAR) is a substrate of EGFR in glioma cells. In response to EGF stimulation, EGFR phosphorylated the COOH-terminal domain of GluN2B and thereby enhanced glutamate-NMDAR signaling and consequent cell migration in EGFR-overexpressing glioma cells. Treatment with the NMDAR inhibitor MK-801 or the system xc(–) inhibitor sulfasalazine suppressed EGF-elicited glioma cell migration. The administration of sulfasalazine and MK-801 also synergistically suppressed the growth of subcutaneous tumors formed by EGFR-overexpressing glioma cells. Furthermore, shRNA-mediated knockdown of xCT and GluN2B cooperatively prolonged the survival of mice injected intracerebrally with such glioma cells. Our findings thus establish a central role for EGFR in the signaling crosstalk between xCT and GluN2B-containing NMDAR in glioma cells.",
author = "Kentaro Suina and Kenji Tsuchihashi and Juntaro Yamasaki and Shohei Kamenori and Subaru Shintani and Yuki Hirata and Shogo Okazaki and Oltea Sampetrean and Eishi Baba and Koichi Akashi and Yoichiro Mitsuishi and Fumiyuki Takahashi and Kazuhisa Takahashi and Hideyuki Saya and Osamu Nagano",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/cas.13826",
language = "English",
volume = "109",
pages = "3874--3882",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate–sensitive glutamate receptor signaling

AU - Suina, Kentaro

AU - Tsuchihashi, Kenji

AU - Yamasaki, Juntaro

AU - Kamenori, Shohei

AU - Shintani, Subaru

AU - Hirata, Yuki

AU - Okazaki, Shogo

AU - Sampetrean, Oltea

AU - Baba, Eishi

AU - Akashi, Koichi

AU - Mitsuishi, Yoichiro

AU - Takahashi, Fumiyuki

AU - Takahashi, Kazuhisa

AU - Saya, Hideyuki

AU - Nagano, Osamu

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas. System xc(–) consists of xCT and CD98hc subunits and functions as a plasma membrane antiporter for the uptake of extracellular cystine in exchange for intracellular glutamate. We previously showed that the EGF receptor (EGFR) interacts with xCT and thereby promotes the activity of system xc(–) in a kinase-independent manner, resulting in enhanced glutamate release in glioma cells. However, the molecular mechanism underlying EGFR-mediated glioma progression in a glutamate-rich microenvironment has remained unclear. Here we show that the GluN2B subunit of the N-methyl-d-aspartate–sensitive glutamate receptor (NMDAR) is a substrate of EGFR in glioma cells. In response to EGF stimulation, EGFR phosphorylated the COOH-terminal domain of GluN2B and thereby enhanced glutamate-NMDAR signaling and consequent cell migration in EGFR-overexpressing glioma cells. Treatment with the NMDAR inhibitor MK-801 or the system xc(–) inhibitor sulfasalazine suppressed EGF-elicited glioma cell migration. The administration of sulfasalazine and MK-801 also synergistically suppressed the growth of subcutaneous tumors formed by EGFR-overexpressing glioma cells. Furthermore, shRNA-mediated knockdown of xCT and GluN2B cooperatively prolonged the survival of mice injected intracerebrally with such glioma cells. Our findings thus establish a central role for EGFR in the signaling crosstalk between xCT and GluN2B-containing NMDAR in glioma cells.

AB - Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas. System xc(–) consists of xCT and CD98hc subunits and functions as a plasma membrane antiporter for the uptake of extracellular cystine in exchange for intracellular glutamate. We previously showed that the EGF receptor (EGFR) interacts with xCT and thereby promotes the activity of system xc(–) in a kinase-independent manner, resulting in enhanced glutamate release in glioma cells. However, the molecular mechanism underlying EGFR-mediated glioma progression in a glutamate-rich microenvironment has remained unclear. Here we show that the GluN2B subunit of the N-methyl-d-aspartate–sensitive glutamate receptor (NMDAR) is a substrate of EGFR in glioma cells. In response to EGF stimulation, EGFR phosphorylated the COOH-terminal domain of GluN2B and thereby enhanced glutamate-NMDAR signaling and consequent cell migration in EGFR-overexpressing glioma cells. Treatment with the NMDAR inhibitor MK-801 or the system xc(–) inhibitor sulfasalazine suppressed EGF-elicited glioma cell migration. The administration of sulfasalazine and MK-801 also synergistically suppressed the growth of subcutaneous tumors formed by EGFR-overexpressing glioma cells. Furthermore, shRNA-mediated knockdown of xCT and GluN2B cooperatively prolonged the survival of mice injected intracerebrally with such glioma cells. Our findings thus establish a central role for EGFR in the signaling crosstalk between xCT and GluN2B-containing NMDAR in glioma cells.

UR - http://www.scopus.com/inward/record.url?scp=85056140032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056140032&partnerID=8YFLogxK

U2 - 10.1111/cas.13826

DO - 10.1111/cas.13826

M3 - Article

C2 - 30298963

AN - SCOPUS:85056140032

VL - 109

SP - 3874

EP - 3882

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -